Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trialAndrew R. Clamp, Jonathan A. Ledermann, Sudha Sundar et al.|The Lancet|2019Cited by 223
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysisA. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2017Cited by 51
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trialAndrew R. Clamp, Jonathan A. Ledermann, Elizabeth C James et al.|The Lancet Oncology|2022Cited by 45
Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trialSarah P. Blagden, Andrew R. Clamp, Adrian Cook et al.|The Lancet Oncology|2020Cited by 37
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatmentAndrew R. Clamp, Jonathan A. Ledermann, Iain A. McNeish et al.|Annals of Oncology|2018Cited by 5